Answers are grounded in this paper and cite their sources.
This randomized trial demonstrates new methods for α-trifluoromethyl amidation and alkene trifluoroalkylamidation, implying enhanced synthetic capabilities for pharmaceutical applications.
Direct catalytic access to α-trifluoromethyl amides from simple fluorinated feedstocks has remained elusive despite the medicinal relevance of this motif. Here, we report the first catalytic platform for direct α-trifluoromethyl amidation through the merger of photochemical halogen-atom transfer (XAT) and nickel-mediated nitrenoid transfer. Under mild conditions, readily available α-bromo-trifluoromethyl alkanes couple with dioxazolones to forge challenging C(sp 3 )-N bonds at α-CF 3 centers with broad functional-group tolerance. The same catalytic manifold further enables a three-component alkene trifluoroalkylamidation, providing modular access to densely functionalized γ-trifluoromethyl alkylamides. Mechanistic studies support a pathway involving photochemically generated α-CF 3 alkyl radicals and nickel-nitrenoid intermediates. Gram-scale synthesis, late-stage functionalization of natural product- and drug-derived substrates, and concise conversion to pharmaceutically relevant analogues underscore the synthetic utility of the platform.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: